参考文献/References:
[1] Wang LL, Zhou W, Zhao W, et al. Clinical features and genetic analysis of 20 Chinese patients with Xlinked HyperIgM syndrome[J]. J Immunol Res, 2014, 2014(257):683160.
[2] 唐文静. 赵晓东.高IgM综合征发病机制研究进展[J]. 国际儿科学杂志, 2013, 40(1):1013.
\[3\] 陈同辛, 金莹莹. 高IgM综合征研究进展[J]. 中华实用儿科临床杂志, 2012, 27(21):16241628.
\[4\] An Y,Xiao J,Jiang L,et al.Clinical and molecular characterization of Xlinked hyperIgM syndrome patents in China[J].Scand J Irnmunol,2010,72(1):5056.
\[5\] Winkelstein JA, Marino MC, Ochs H, et al. The Xlinked hyperIgM syndrome: clinical and immunologic features of 79 patients[J]. Medicine, 2003, 82(6):373384.
[6] Hubbard N, Hagin D, Sommer K, et al. Targeted gene editing restores regulated CD40L function in Xlinked hyperIgM syndrome[J]. Blood, 2016, 127(21):2513.
[7] Yong PFK, Post FA, Gilmour KC, et al. Cerebral toxoplasmosis in a middleaged man as first presentation of primary immunodeficiency due to a hypomorphic mutation in the CD40 ligand gene[J]. Journal of Clinical Pathology, 2008, 61(11):12201222.
[8] LopezHerrera G, MaravillasMontero JL, VargasHernández A, et al. A novel CD40LG deletion causes the hyperIgM syndrome with normal CD40L expression in a 6monthold child[J]. Immunologic Research, 2015, 62(1):16.
[9] 赵晓东.采用高通量测序技术发现、筛查与诊断原发性免疫缺陷病[J].中华实用儿科临床杂志,2015,30(9):644647.
[10] 姜向阳, 李兴珍, 刘文康,等. 高通量测序平台对卵巢癌基因突变的检测及意义[J]. 陕西医学杂志, 2017, 46(10):13461348.
[11] Durandy A, Kracker S. Immunoglobulin classswitch recombination deficiencies[J]. Arthritis Research & Therapy, 2010, 135(2):193203.
[12] Levy J, Espanolboren T, Thomas C, et al. Clinical spectrum of Xlinked hyperIgM syndrome[J]. J Pediatr, 1997, 131(1):4754.
[13] Mavroudi I, Papadaki HA. The role of CD40/CD40 ligand interactions in bone marrow granulopoiesis[J]. The Scientific World Journal, 2011, 11(10):20112019.
[14] Solanilla A, Déchanet J, El AA, et al. CD40ligand stimulates myelopoiesis by regulating flt3ligand and thrombopoietin production in bone marrow stromal cells[J]. Blood, 2000, 95(12):37583764.
[15] Ziegner UH, Kobayashi RH, CunninghamRundles C, et al. Progressive neurodegeneration in patients with primary immunodeficiency disease on IVIG treatment[J]. Clinical Immunology, 2002, 102(1):1924.
[16] Lee WI, Huang JL, Yeh KW, et al. Clinical features and genetic analysis of Taiwanese patients with the hyper IgM syndrome phenotype[J]. Pediatric Infectious Disease Journal, 2013, 32(9):10101016.
[17] CabralMarques O, Klaver S, Schimke LF, et al. First report of the HyperIgM syndrome registry of the latin American society for immunodeficiencies: Novel mutations, unique infections, and outcomes[J]. Journal of Clinical Immunology, 2014, 34(2):146156.
[18] Madkaikar M, Gupta M, Chavan S, et al. Xlinked hyper IgM syndrome: clinical, immunological and molecular features in patients from India[J]. Blood Cells Molecules & Diseases, 2014, 53(3):99104.
[19] AlSaud B, AlMousa H, AlAhmari A, et al. Hematopoietic stem cell transplant for hyperIgM syndrome due to CD40L defects: A single center experience[J]. Pediatric Transplantation, 2015, 19(6):634639.
[20] Allewelt H, Martin PL, Szabolcs P, et al. Hematopoietic stem cell transplantation for CD40 ligand deficiency: Single institution experience[J]. Pediatric Blood & Cancer, 2015, 62(12):22162222.
[21] Mt DLM, Leonard D, Torgerson TR, et al. Longterm outcomes of 176 patients with Xlinked hyperIgM syndrome treated with or without hematopoietic cell transplantation[J]. Journal of Allergy & Clinical Immunology, 2016, 139(4):12821292.
[22] MitsuiSekinaka K, Imai K, Sato H, et al. Clinical features and hematopoietic stem cell transplantations for CD40 ligand deficiency in Japan[J]. Journal of Allergy & Clinical Immunology, 2015, 136(4):10181024.